Hepatocellular carcinoma in non-alcoholic fatty liver disease with and without cirrhosis

Abstract

Non-alcoholic fatty liver disease has become the leading chronic liver disease in the developed world, with a prevalence of 6%-35%. Its pathological spectrum ranges from simple steatosis (non-alcoholic fatty liver) to different degrees of inflammation and liver cell damage [non-alcoholic steatohepatitis (NASH)]. NASH has gained attention in recent years because of its association with hepatocellular carcinoma (HCC). Although the occurrence of HCC is more frequent in the presence of cirrhosis, studies have shown that hepatic carcinogenesis may also develop in the context of NASH without association with advanced fibrosis, as well as from simple steatosis. Evidence of the onset of HCC in the absence of cirrhosis is of concern, since recent surveillance and screening guidelines for liver cancer do not include this population subgroup. Therefore, it is imperative that new effective screening and monitoring measures for HCC, or even the reformulation of these recommendations, be taken to handle these patients considered to be at high risk. The present paper aims to review the literature on the occurrence of HCC in patients with NASH with or without cirrhosis. In addition, we report a case showing the development of HCC in a patients with NASH without cirrhosis.

Keywords

Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis / cirrhosis / hepatocellular carcinoma

References

[1] Stine JG,Zimmet A,Loomba R.Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases..Aliment Pharmacol Ther2018;48:696-703

[2] Cholankeril G,Khurana S.Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management..World J Hepatol2017;9:533-43 PMCID:PMC5395802

[3] Chagas AL,Oliveira CP,Mello ES.Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?.Braz J Med Biol Res2009;42:958-62

[4] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease..J Hepatol2016;64:1388-402

[5] Oda K,Mawatari S.Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies..Clin J Gastroenterol2015;8:1-9

[6] Chu H,Schnabl B.Gut microbiota, fatty liver disease, and hepatocellular carcinoma..Liver Res2018;2:43-51 PMCID:PMC6223644

[7] Perumpail RB,Ahmed A.Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience..Dig Dis Sci2015;60:3142-8

[8] Yatsuji S,Tobari M,Tokushige K.Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C..J Gastroenterol Hepatol2009;24:248-54

[9] Ascha MS,Lopez R,Feldstein AF.The incidence and risk factors of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis..Hepatology2010;51:1972-8

[10] Mahady SE.Burden of non-alcoholic fatty liver disease in Australia..J Gastroenterol Hepatol2018;33:1-11

[11] Piñero F,Marciano S,Silva J.Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina..World J Hepatol2018;10:41-50 PMCID:PMC5787683

[12] Cotrim HP,Figueiredo-Mendes C,Porta G.Nonalcoholic fatty liver disease brazilian society of hepatology consensus..Arq Gastroenterol2016;53:118-22

[13] Said A.Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma..World J Clin Oncol2017;8:429-36 PMCID:PMC5740098

[14] Kanwal F,Mapakshi S,Chayanupatkul M.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease..Gastroenterology2018;155:1828-37 PMCID:PMC6279617

[15] Ioannou GN,Lowy E,Berry K.Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis..PLoS One2018;13:0204412 PMCID:PMC6160079

[16] Reig M,Man NK,Victor D.Should patients with NAFLD/NASH be surveyed for HCC?.Transplantation2019;103:39-44

[17] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes..Hepatology2016;64:73-84

[18] Malik VS,Hu FB.Global obesity: trends, risk factors and policy implications..Nat Rev Endocrinol2013;9:13-27

[19] Fan JG,Wong VW.New trends on obesity and NAFLD in Asia..J Hepatol2017;67:862-73

[20] Wong SW,Chan WK.Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications..JGH Open2018;2:235-41 PMCID:PMC6206984

[21] Bulathsinhala BKS,Gunetilleke MB,Dassanayake A.Clinical characteristics and outcomes of hepatocellular carcinoma: results from prospective study, from a tertiary referral center in Sri Lanka..Ceylon Med J2018;63:133-8

[22] Mak LY,Chinchilla-López P,LoConte NK.Global epidemiology, prevention, and management of hepatocellular carcinoma..Am Soc Clin Oncol Educ Book2018;23:262-79

[23] Argyrou C,Vernadakis S.Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the “Plague” of the 21st century? A literature review focusing on pathogenesis, prevention and treatment..J BUON2017;22:6-20

[24] Massoud O.Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis and hepatocellular carcinoma..Clin Liver Dis2018;22:201-11

[25] Rawla P,Muralidharan P.Update in global trends and aetiology of hepatocellular carcinoma..Contemp Oncol (Pozn)2018;22:141-50 PMCID:PMC6238087

[26] Nakagawa H,Kawamura S,Fujiwara N.Lipid metabolic reprogramming in hepatocellular carcinoma..Cancers (Basel)2018; PMCID:PMC6265967

[27] Reeves HL,Day CP.Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD..Dig Dis Sci2016;61:1234-45

[28] Thompson SM,Ehman EC,Bookwalter CA.Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI..Br J Radiol2018;91:20180345 PMCID:PMC6319849

[29] Sadler EM,Bhat M,Greig PD.Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma..Transplantation2018;102:640-7

[30] Wong CR,Nguyen MH,Lim JK.Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease..Aliment Pharmacol Ther2017;46:1061-9

[31] Tavakoli H,Liu B,Younossi Z.Cirrhosis patients with nonalcoholic steatohepatitis are significantly less likely to receive surveillance for hepatocellular carcinoma..Dig Dis Sci2017;62:2174-81

[32] Balbinot RS,Dal Castel M,Balbinot RA.Intraparenchymal hemorrhage due to brain metastasis of hepatocellular carcinoma..Case Rep Gastroenterol2017;11:516-25 PMCID:PMC5637007

[33] Soldera J,Balbinot RA,Terres AZ.Advanced hepatocellular carcinoma..Austin J Gastroenterol2017;4:1088

[34] Soldera J,Balbinot RA.Diagnostic and therapeutic approaches to hepatocellular carcinoma: understanding the Barcelona Clinic Liver Cancer Protocol..Clin Med Insights Gastroenterol2016;9:67-71 PMCID:PMC5084833

[35] Chalasani N,Lavine JE,Cusi K.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases..Hepatology2018;67:328-57

[36] Pais R,Goumard C,Wendum D.Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period..Aliment Pharmacol Ther2017;46:856-63

[37] Schütte K,Poranzke J,Bornschein J.Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver..BMC Gastroenterol2014;14:117 PMCID:PMC4098694

[38] Leung C,Patrick D,Marion K.Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease..World J Gastroenterol2015;21:1189-96 PMCID:PMC4306163

[39] Bertot LC,Wallace M,Garas G.Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma..Hepatol Commun2017;1:53-60 PMCID:PMC5747027

[40] Edenvik P,Oksanen A,Hultcrantz R.Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?.Liver Int2015;35:1862-71

[41] Mohamad B,Onyshchenko M,Aucejo F.Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis..Hepatol Int2016;10:632-9

[42] Zarrinpar A,Agopian VG,Harlander-Locke MP.Metabolic factors affecting hepatocellular carcinoma in steatohepatitis..Liver Int2018;

[43] Kwon OS,Kim JH.The development of hepatocellular carcinoma in non-alcoholic fatty liver disease..Korean J Gastroenterol2017;69:348-52(in Korean)

[44] Kawaguchi T,Hyogo H,Nakajima T.A data mining-based prognostic algorithm for NAFLD-related hepatoma patients: a nationwide study by the Japan study group of NAFLD..Sci Rep2018;8:10434 PMCID:PMC6041283

[45] Huang Y,Adams LA,Garas G.Rate of nonsurveillance and advanced hepatocellular carcinoma at diagnosis in chronic liver disease..J Clin Gastroenterol2018;52:551-6

[46] Roskilly A.Surveillance for hepatocellular cancer..Clin Med (Lond)2018;18:s66-9 PMCID:PMC6334024

[47] Younes R.Should we undertake surveillance for HCC in patients with NAFLD?.J Hepatol2018;68:326-34